Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 4, 2025

Primary Completion Date

July 4, 2026

Study Completion Date

July 4, 2026

Conditions
Diabetic Peripheral NeuropathyDiabetic NeuropathyDiabetic Peripheral Neuropathy in Type 2 Diabetic Patients
Interventions
DRUG

Melatonin

"Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway.~Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice."

Trial Locations (1)

Unknown

RECRUITING

Ain Shams University hospital, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT07036796 - Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter